The Claim
In human lung adenocarcinoma tissues, PCK2 and SLC38A2 expression levels are significantly higher than in adjacent non-tumor tissues, and the expression levels of PCK2 and SLC38A2 are positively correlated.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In human lung cancer tissues, the levels of two proteins, PCK2 and SLC38A2, are higher than in nearby healthy lung tissue, and the amounts of these two proteins increase together.
See the scientific wording
In human lung adenocarcinoma tissues, PCK2 and SLC38A2 expression levels are significantly higher than in adjacent non-tumor tissues, and their expression levels are positively correlated, suggesting a clinical association between this metabolic pathway and tumor presence.
When glucose is scarce, cancer cells in the lung produce more PCK2, which turns on AMPK, which then activates CEBPB. CEBPB turns up the production of SLC38A2, a protein that pulls glutamine into the cell. The glutamine feeds into energy production pathways, allowing the cancer cells to keep making energy and grow even without glucose.
What the research says
1 studyThe study found that two proteins, PCK2 and SLC38A2, are more common in lung cancer tumors than in healthy lung tissue, and that when one is high, the other tends to be high too — just like the claim says. It also shows how one protein helps turn on the other, explaining why they work together in cancer.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.